AMYT Stock Overview
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases.
Amryt Pharma plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.66|
|52 Week High||US$12.45|
|52 Week Low||US$5.61|
|1 Month Change||3.24%|
|3 Month Change||-6.70%|
|1 Year Change||-28.74%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-3.65%|
Recent News & Updates
Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.
|AMYT||US Pharmaceuticals||US Market|
Return vs Industry: AMYT underperformed the US Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: AMYT underperformed the US Market which returned -11.7% over the past year.
|AMYT Average Weekly Movement||5.6%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: AMYT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: AMYT's weekly volatility (6%) has been stable over the past year.
About the Company
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB.
Amryt Pharma plc Fundamentals Summary
|AMYT fundamental statistics|
Is AMYT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AMYT income statement (TTM)|
|Cost of Revenue||US$116.17m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.044|
|Net Profit Margin||1.17%|
How did AMYT perform over the long term?See historical performance and comparison